Meeting ReportIn vitro and In vivo Oncology

The journey to a novel theranostic for prostate cancer : the preclinical study of 64Cu-DOTHA2-PSMA

Marie-Christine Milot, Ophelie Belissant Benesty, Veronique Dumulon-Perreault, Samia Ait-Mohand, Sameh Geha, Patrick Richard, Etienne Rousseau and Brigitte Guerin
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4025;

Article Information

vol. 63 no. supplement 2 4025
Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online August 8, 2022.
Copyright & Usage 
© 2022

Author Information

  1. Marie-Christine Milot1,
  2. Ophelie Belissant Benesty2,
  3. Veronique Dumulon-Perreault3,
  4. Samia Ait-Mohand2,
  5. Sameh Geha2,
  6. Patrick Richard2,
  7. Etienne Rousseau2 and
  8. Brigitte Guerin4
  1. 1Departement de Medecine Nucleaire Et Radiobiologie
  2. 2Universite de Sherbrooke
  3. 3Centre d'Imagerie Moléculaire de Sherbrooke
  4. 4Université de Sherbrooke

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: August 2022 to April 2025

AbstractFullPdf
Aug 20223100
Sep 20221700
Oct 2022600
Nov 20221900
Dec 20221300
Jan 20232100
Feb 20232600
Mar 2023800
Apr 20231000
May 2023800
Jun 2023600
Jul 2023900
Aug 20231000
Sep 20231700
Oct 2023700
Nov 2023400
Dec 20231000
Jan 2024600
Feb 20241300
Mar 20241000
Apr 20243600
May 2024900
Jun 20242800
Jul 202410900
Aug 20248400
Sep 20241700
Oct 2024700
Nov 20241500
Dec 20241100
Jan 2025600
Feb 2025400
Mar 2025700
Apr 20251700
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section